证券代码：000423 证券简称：东阿阿胶 公告编号：2025-80 东阿阿胶股份有限公司 关于回购股份用于注销并减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 12 月 4 日召开第 十一届董事会第十五次会议及 2025 年 12 月 22 日召开 2025 年第二次临时股东 会，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。具体 内容，详见公司在巨潮资讯网（http://www.cninfo.com.cn）上披露的《第十 一届董事会第十五次会议决议公告》《关于以集中竞价交易方式回购公司股份 方案的公告》《2025 年第二次临时股东会决议公告》《关于以集中竞价交易方 式回购股份的回购报告书》等相关公告。 根据回购方案，公司拟通过深圳证券交易所交易系统以集中竞价交易方式 回购公司境内发行上市人民币普通股（A 股）股票，回购资金总额不超过人民 币 20,000 万元（含），不低于人民币 10,000 万元（含），回购股份价格不超 过人民币 72.08 元/股（ ...

北京金诚同达律师事务所 关于 东阿阿胶股份有限公司 2025 年第二次临时股东会的 法律意见书 北京市朝阳区建国门外大街 1 号国贸大厦 A 座 10 层 电话：010-5706 8585 传真：010-6518 5057 金诚同达律师事务所 法律意见书 北京金诚同达律师事务所 关于东阿阿胶股份有限公司 2025 年第二次临时股东会的 法律意见书 金证法意[2025]字 1222 第 1062 号 致：东阿阿胶股份有限公司 北京金诚同达律师事务所（以下简称"本所"）接受东阿阿胶股份有限公司 （以下简称"东阿阿胶"或"公司"）的聘请，指派本所律师出席公司 2025 年 第二次临时股东会（以下简称"本次股东会"）并对会议的相关事项出具法律意 见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）、 《律师事务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则 （试行）》等有关法律、法规和规范性文件的要求以及《东阿阿胶股份有限公司 章程》（以下简称"《公司章程》"）的规定，对本次股东会的召集、召开程序， 出席会 ...

东阿阿胶股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东会无否决议案。 2．本次股东会不涉及变更以往股东会已通过的决议。 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-79 （一）现场会议召开时间：2025 年 12 月 22 日 09:30 （二）现场会议召开地点：公司会议室 （三）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年12 月22日上午9:15—9:25、9:30—11:30，下午13:00-15:00；通过深圳证券交易所 互联网投票系统投票的时间为2025年12月22日9:15-15:00期间的任意时间。 （四）召开方式：采用现场表决和网络投票相结合的方式。 （五）会议的召集与主持情况：本次会议由公司董事会召集，公司董事会过 半数的董事推举董事、总裁孙金妮女士主持。 （六）会议的合法合规性：本次股东会的召集和召开，符合《公司法》《上 市公司股东会规则》《深圳证券交易所股票上市规则》及《公司章程》等法律法 规及规范性文件的规定。 （七）会议 ...

东阿阿胶公告称，公司拟以集中竞价交易方式回购股份，回购资金总额不低于1亿元、不超过2亿元，回 购价格不超过72.08元/股，预计回购数量为138.73-277.47万股，约占总股本的0.22%-0.43%。回购股份将 全部注销并减少注册资本，实施期限自股东会审议通过起不超12个月。公司控股股东等未来3个月、6个 月内均无减持计划。本次回购存在股价超上限、债权人要求清偿或担保、重大事项发生等风险。 ...

Group 1 - The Super Brand concept index declined by 0.48%, ranking among the top declines in concept sectors, with notable declines in stocks such as Aucma, Zhonggong Education, and TCL Technology [1] - Among the Super Brand concept stocks, 13 stocks saw price increases, with Anfu Technology, SF Holding, and Dong'e Ejiao leading the gains at 2.40%, 1.22%, and 1.11% respectively [1] - The Super Brand concept experienced a net outflow of 1.662 billion yuan from main funds, with 32 stocks facing net outflows, and 7 stocks seeing outflows exceeding 100 million yuan [2] Group 2 - The top net outflow stocks included China Mobile, TCL Technology, and Kweichow Moutai, with net outflows of 359.45 million yuan, 219.80 million yuan, and 155.96 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included SF Holding, Dong'e Ejiao, and Yunnan Baiyao, with net inflows of 89.39 million yuan, 34.34 million yuan, and 14.78 million yuan respectively [2] - The trading volume for China Mobile was 2.28%, while TCL Technology had a turnover rate of 2.06% [3]

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1][42]. Core Insights - There is a recovery in demand for clinical research organizations (CROs), while the supply of experimental monkeys is tight, leading to price increases. The domestic financing for innovative drugs is gradually recovering, with a total financing amount of $4.086 billion from January to November 2025, representing a year-on-year increase of 10.6% [1][10]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.49% against the CSI 300's 16.09% [22]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 profit forecasts, which is a 41% premium over the overall A-share market (excluding financials) [23]. Summary by Sections Recent Trends - The CSI 300 index fell by 0.28% this week, while the pharmaceutical sector decreased by 0.14%, ranking 22nd among 31 primary sub-industries. The weekly performance of sub-sectors includes declines in chemical pharmaceuticals and biological products, while medical services and medical commerce showed gains [9][22]. Market Dynamics - The demand for CROs is recovering, and the supply of experimental monkeys is limited, with prices for 3-5 year old monkeys reaching 140,000 yuan each. This indicates a recovery in the domestic innovative drug research and development environment [10][11]. Valuation - The pharmaceutical sector's current valuation is 29.1 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE. The sector has a 17.2% premium over the overall A-share market [23]. Company Performance - Notable performers in the pharmaceutical commercial sector this week include Huaren Health, Luyuan Pharmaceutical, and Shuyuan Pingmin, with significant weekly gains [25]. Key Company Meetings - Upcoming shareholder meetings include Dong'e Ejiao, Zhonghe Holdings, and Yiling Pharmaceutical on December 22, among others [31][32][33].

Core Viewpoint - The concept of "food and medicine sharing the same source" is gaining popularity, leading to increased demand for health products, particularly ready-to-eat Ejiao products, driven by various consumer demographics including the elderly, women, and Gen Z [1][8]. Market Overview - The ready-to-eat Ejiao market in China is projected to reach a scale of 54.3 billion yuan in 2024, representing a year-on-year growth of 22.3%, accounting for 25% of the overall ready-to-eat health product market [1][8]. - Ready-to-eat Ejiao is produced through optimized formulations and improved processes, making it convenient for modern lifestyles [2][3]. Market Policies - Recent policies emphasize food safety and quality control across all stages of production, processing, and distribution of ready-to-eat Ejiao, promoting a shift towards standardized and high-quality industry practices [4][5]. Industry Chain - The upstream of the ready-to-eat Ejiao industry includes suppliers of key raw materials such as donkey hide, black sesame, walnuts, red dates, honey, and rock sugar, while the midstream consists of production companies, and the downstream includes various sales channels [6][7]. Current Development - The demand for ready-to-eat Ejiao is expanding beyond traditional consumers to include working professionals and younger generations, with consumption scenarios evolving to include daily snacks and gift-giving [8][9]. Competitive Landscape - The ready-to-eat Ejiao market is characterized by a concentrated competitive structure, dominated by two major players, Dong'e Ejiao and Fupai Ejiao, which control key raw material supplies and have established strong brand loyalty [10]. - Dong'e Ejiao reported a revenue of 3.051 billion yuan in the first half of 2025, with 93.2% of this coming from Ejiao and related products [11]. - Fupai Ejiao achieved a revenue of 2.104 billion yuan in 2024, marking a 5% increase, with over 40% of sales coming from non-Ejiao block products [12]. Future Trends - The ready-to-eat Ejiao product line is expected to diversify further, introducing more portable and snack-like options, while also targeting specific consumer needs such as prenatal nutrition and weight management [13]. - The international market for ready-to-eat Ejiao is anticipated to expand, initially targeting regions with high Chinese populations and gradually moving towards Western markets [13].

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-78 东阿阿胶股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东 持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 12 月 4 日召开第十 一届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》,并同意将该议案提交公司 2025 年第二次临时股东会审议。具体内 容，详见公司于 2025 年 12 月 5 日披露在巨潮资讯网（http://www.cninfo.com.cn） 的《关于以集中竞价交易方式回购公司股份方案的公告》（2025-72）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现将公司 2025 年第二次临时股东会股权登记 日（2025 年 12 月 15 日）登记在册的前十名股东和前十名无限售条件股东的名 称、持股数量及比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本 比例（%） | | ...

让"大国胶香"惠及更多民众 人民健康是社会文明进步的基础，是民族昌盛和国家富强的重要标志。 作为华润集团大健康板块的重要成员和胶类中药代表性企业，东阿阿胶胸怀"国之大者"使命担当，积极 响应"健康中国"战略。 创新逐梦未来，科技点燃东阿。 近日，2025东阿阿胶科技创新大会在山东东阿隆重举行；在此之前，石碧院士工作站、陈卫院士工作站 相继落地东阿阿胶……东阿阿胶将科技创新摆在"C位"，研发创新模式从"点状突破"向"系统重构"的战 略升级，为公司高质量发展注入强劲科技动能。 在健康中国战略的宏大叙事中，科技创新正成为推动传统滋补行业转型升级的核心驱动力。东阿阿胶， 这一承载着千年滋补文化底蕴的民族品牌，以"寿人济世"为使命担当，将传统智慧与现代科技深度融 合，以开放创新的姿态，书写着服务国家战略、增进人类健康福祉的时代答卷。 2022年以来，在华润集团"1246"模式指引下，实施了一系列大刀阔斧的重塑革新，提出"1238"战略，东 阿阿胶确定了药品+健康消费品"双轮驱动"的业务增长模式，立志成为"大众最信赖的滋补健康引领 者"，推动胶类中药产业高质量发展。 战略方向明确了，核心抓手则落脚在"科技创新"四个字上， ...

Group 1 - The company Dong-E E-Jiao has been awarded the title of "National Advanced Unit for Mass Sports" for the period of 2021-2024 by the General Administration of Sport of China, recognizing its efforts in promoting health services and mass fitness activities [1][3] - Dong-E E-Jiao has actively implemented the "Strong Sports Nation" strategy and has committed to safeguarding public health by organizing various employee sports activities and supporting high-quality development in sports [3] - Starting in 2024, Dong-E E-Jiao will establish a strategic partnership with the Shandong Provincial Sports Bureau, sponsoring the Shandong team in the National Super League and the Shandong Marathon, while also becoming a strategic partner for the Shandong delegation at the 15th National Games [3] Group 2 - The company's core products, including "Dong-E E-Jiao," "Compound E-Jiao Syrup," and "Peach Blossom Princess E-Jiao Cake," have been designated as the official products for the Shandong sports delegation at the 15th National Games [3] - Dong-E E-Jiao is planning to build employee health service centers and is focused on enhancing the physical fitness and health levels of its employees through various sports activities [3] - The company aims to integrate traditional Chinese medicine with sports health initiatives, driving innovation in the TCM sector and contributing to the national health development strategy [3]